{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menieres-disease/management/management/","result":{"pageContext":{"chapter":{"id":"ed30823a-3e70-58a0-9411-f17351fb2c44","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 13761eb2-28e4-4c89-b4fb-e890f06d8a70 --><h2>Scenario: Management of Meniere's disease</h2><!-- end field 13761eb2-28e4-4c89-b4fb-e890f06d8a70 -->","summary":"Covers the management of people with acute and recurrent attacks of Meniere's disease and includes information on how to try to prevent attacks.","htmlStringContent":"<!-- begin item ab3e4d2a-a448-4cce-b862-0b2ee34b70ab --><!-- begin field 620e8ed0-8fb6-4372-b2f7-acbc0157b08c --><p>From age 18 years onwards.</p><!-- end field 620e8ed0-8fb6-4372-b2f7-acbc0157b08c --><!-- end item ab3e4d2a-a448-4cce-b862-0b2ee34b70ab -->","topic":{"id":"c2b20ab8-7e5a-5868-9804-8a9d6a2cb567","topicId":"193a65ca-1981-44e6-a5d3-781aa5010b2c","topicName":"Meniere's disease","slug":"menieres-disease","lastRevised":"Last revised in November 2017","chapters":[{"id":"16b06288-e565-5867-9311-37b626851eb0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"47494f3b-a0fd-53b2-8613-2cd38f1a11dd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"371c2958-24a9-5d9c-ae14-b7539d491674","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d13d990c-bded-5655-aa70-40268a150cbd","slug":"changes","fullItemName":"Changes"},{"id":"c184f0c8-2419-565f-ab73-a1a5591fc29d","slug":"update","fullItemName":"Update"}]},{"id":"9c1b726a-8066-5632-89ef-7764e1edd1d3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8ee08c5c-67dd-57f0-b666-7d874024d8ed","slug":"goals","fullItemName":"Goals"},{"id":"7fd84935-e76b-56af-b285-b58ed2a8ecc2","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"981ad1f7-1003-50fc-8e49-411ea1ff34d4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"4307ba4c-2b7b-54c0-9103-71e4a18f16ac","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"416a0198-b8a8-5272-8684-3aa5a380fc74","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2221f812-317a-569e-a4bc-0183f833d0f7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"272bf558-6edb-531a-a2d4-4b19639383ad","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"25e37eb8-40b6-5b11-b9d3-4fe5378e1524","slug":"definition","fullItemName":"Definition"},{"id":"65d7cb18-66af-5447-8401-2c8e24d64dd4","slug":"cause","fullItemName":"Cause"},{"id":"4f2a2237-790f-5b99-9650-34b58a75512e","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ed8dbd0f-7c6b-53bf-a2b9-77006586ab7e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a4342e8b-12e6-56d8-a716-190cac3ce652","slug":"complications","fullItemName":"Complications"},{"id":"5b357eed-7df9-57ca-9c0d-0511ecf6f601","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"318e7c3d-c3c6-5a60-be9d-9179e643d3fb","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"0ae90882-dae2-56da-b987-8bca0eefb6b3","slug":"suspecting-menieres-disease","fullItemName":"Suspecting Meniere's disease"},{"id":"7fc93a60-260c-5030-a14e-d6375907f198","slug":"making-a-diagnosis","fullItemName":"Making a diagnosis"},{"id":"73c5b8af-f846-541f-a7d9-48e2c6b9679c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f2772f3-1ee5-5ca8-8c0c-bb2454b53670","fullItemName":"Management","slug":"management","subChapters":[{"id":"ed30823a-3e70-58a0-9411-f17351fb2c44","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"0b1be20b-b94c-56a6-a221-cbea038b74ec","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"2054a7c4-97a4-57e7-a3de-05ea67cfa502","slug":"betahistine","fullItemName":"Betahistine"},{"id":"2e656ebe-784a-562f-8aca-85a4aa0f56bb","slug":"cinnarizine","fullItemName":"Cinnarizine"},{"id":"73881eee-9a58-575f-9d06-545fa1f67335","slug":"cyclizine","fullItemName":"Cyclizine"},{"id":"584ce48e-7ea7-5ee0-874b-1c99ccbdb8fa","slug":"prochlorperazine","fullItemName":"Prochlorperazine"},{"id":"0c353f7c-323c-5e3b-9872-1e6533f5abad","slug":"promethazine-teoclate","fullItemName":"Promethazine teoclate"}]},{"id":"5de25a19-1810-510b-ba6b-c9b9979fb4c6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f893c00d-a15b-572d-8042-6164f0ee4141","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"18f58ee1-0ff6-5c45-b4a3-5f2f22070e03","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"41de5190-f85f-57eb-81a1-fa4aad3af7b5","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"9e4161b0-4719-5539-99e5-e094855a17d0","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5a5f7056-1236-5638-904d-dce7e2b843af","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"2b63dcde-7589-5a5a-b219-7f2ff2e0b527","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8a8e9bf2-d409-5815-8467-31e3a6379930","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3f2772f3-1ee5-5ca8-8c0c-bb2454b53670","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"2941305d-9dbe-5ca9-a5c7-fff3fe7b5be6","slug":"when-to-refer","fullItemName":"When to refer","depth":3,"htmlHeader":"<!-- begin field 14d9f25c-88a6-4901-95b7-f4b402e07bcd --><h3>When should I refer?</h3><!-- end field 14d9f25c-88a6-4901-95b7-f4b402e07bcd -->","summary":null,"htmlStringContent":"<!-- begin item 2c983e79-98c5-4613-ad39-7473a49890c6 --><!-- begin field e0a5c418-0c7b-4dfc-b48c-6e7ff56ebddf --><ul><li><strong>Admit people with severe symptoms to hospital </strong>for intravenous (IV) labyrinthine sedatives and fluids to maintain hydration, and nutrition.</li><li><strong>To confirm the diagnosis of Meniere's disease, </strong>refer the person to an Ear, Nose, and Throat (ENT) consultant.</li><li><strong>If the person has symptoms and signs suggestive of hearing loss </strong>— refer for an audiology assessment, if not already carried out by ENT services.</li><li><strong>Ideally involve the support of the multidisciplinary healthcare team </strong>for example ENT, physiotherapist, hearing therapist, audiologist, counsellor, or psychologist early on so that people can benefit from their expertise.<ul><li>Availability of some multidisciplinary support services may vary depending on locality.</li></ul></li></ul><!-- end field e0a5c418-0c7b-4dfc-b48c-6e7ff56ebddf --><!-- end item 2c983e79-98c5-4613-ad39-7473a49890c6 -->","subChapters":[{"id":"1cf8d5ba-b316-532b-a10c-447d3f9de62b","slug":"basis-for-recommendation-207","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field c37170f3-5acf-495b-bed1-07c246894d3e --><h4>Basis for recommendation</h4><!-- end field c37170f3-5acf-495b-bed1-07c246894d3e -->","summary":null,"htmlStringContent":"<!-- begin item 20756a1c-b153-430e-abbd-f9bbed287c90 --><!-- begin field 5b695fbe-27cb-49dc-b9b1-a50a958c2394 --><h5>Hospital admission for severe symptoms</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice.</li></ul><h5>Referral for confirmation of the diagnosis</h5><ul><li>Experts acknowledge that the diagnosis of Meniere's disease is challenging because of the remitting and relapsing nature of the disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Wipperman, 2014</a>]. CKS recommends referral to an ear, nose, and throat specialist for confirmation of the diagnosis based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">van Vugt et al, 2017</a>].  </li><li>Other investigations may also be required in order to exclude other causes of vertigo before a definite diagnosis of Meniere's disease can be made [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Tassinari et al, 2015</a>]. Expert opinion in diagnostic and therapeutic guidelines from the French Otorhinolaryngology Head and Neck Surgery Society [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Nevoux et al, 2017</a>]<strong> </strong>and review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Wipperman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Gurkov et al, 2016</a>]<strong> </strong>suggests people with suspected Meniere's disease should undergo MRI scanning to exclude acoustic neuroma, cerebellopontine angle or endolymphatic sac tumour, Chiari malformation, or multiple sclerosis. Specialist investigations that may also be used in the diagnosis of Meniere's disease include vestibular testing using electronystagmography or videonystagmography [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Espinosa-Sanchez and Lopez-Escamez, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BMJ Best Practice, 2017</a>].</li></ul><h5>Referral to audiology</h5><ul><li>Sensorineural hearing loss with certain features, confirmed on audiometry is a criterion for a definite diagnosis of Meniere's disease in the Equilibrium Committee Amendment to the 1995 AAO-HNS Guidelines for the Definition of Meniere’s Disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Goebel, 2016</a>]. Audiometry is recommended by many experts to confirm the sensorineural hearing loss found in Meniere's disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Wipperman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Dommaraju and Perera, 2016</a>]. Expert opinion in a review article advises referral to a specialist centre if audiometry is not available in primary care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>]. </li></ul><h5>Involving the multidisciplinary healthcare team</h5><ul><li>This recommendation is pragmatic, and is based on what CKS considers to be good clinical practice. It is supported by information from the Meniere's Society that emphasises the importance of effective communication between the multidisciplinary team (physiotherapists, nurses, doctors, hearing therapists, and dietitians) to achieve effective vestibular rehabilitation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Meniere&#39;s Society, 2013</a>]. </li></ul><!-- end field 5b695fbe-27cb-49dc-b9b1-a50a958c2394 --><!-- end item 20756a1c-b153-430e-abbd-f9bbed287c90 -->","subChapters":[]}]},{"id":"c992ee65-341b-5329-b7f3-bc656b49d2c0","slug":"self-care-advice","fullItemName":"Self-care advice","depth":3,"htmlHeader":"<!-- begin field dd1f53ec-158f-4707-bf67-0b43a7ad3b02 --><h3>What self-care advice should I give someone with Meniere's disease?</h3><!-- end field dd1f53ec-158f-4707-bf67-0b43a7ad3b02 -->","summary":null,"htmlStringContent":"<!-- begin item f67b3957-1d29-4f23-814b-7d01de617351 --><!-- begin field 247ca6ff-01be-4d7e-9f02-389c502e8794 --><ul><li><strong>Reassure the person</strong> that Meniere's disease is a long-term condition, but vertigo usually significantly improves with treatment. </li><li><strong>Advise that an acute attack of vertigo will normally settle within 24 hours in most people</strong>. If there is no improvement after 5–7 days, or there is any deterioration in symptoms, ask the person to return to exclude an alternative diagnosis. </li><li><strong>Advise people experiencing sudden attacks of vertigo</strong> <strong>to:</strong><ul><li>Keep medication readily accessible.</li><li>Consider the risks before undertaking activities such as operating dangerous machinery, using ladders or scaffolding, or going swimming.</li></ul></li><li><strong>Advise the person not to drive when they are dizzy, or if they might experience an episode of vertigo while driving.</strong><ul><li>The Driver and Vehicle Licensing Agency (DVLA) states that people with 'liability to sudden and unprovoked or unprecipitated episodes of disabling dizziness' should stop driving and inform the DVLA. For more information, see the DVLA publication <a data-hyperlink-id=\"65303f20-6f97-488e-a85c-a98d002f8abf\" href=\"https://www.gov.uk/government/publications/assessing-fitness-to-drive-a-guide-for-medical-professionals\">Assessing fitness to drive: a guide for medical professionals.</a></li></ul></li><li><strong>Discuss sources of information and support </strong>for people with Meniere's disease, such as:<ul><li>The <a data-hyperlink-id=\"139f6391-86bc-427c-ae27-a98d002f8af9\" href=\"http://www.menieres.org.uk/\">Meniere's Society</a> (www.menieres.org.uk).</li><li>The <a data-hyperlink-id=\"6156a9bd-0aef-4740-8187-a98d002f8b4c\" href=\"http://www.tinnitus.org.uk/\">British Tinnitus Association</a> (www.tinnitus.org.uk).</li><li><a data-hyperlink-id=\"b37b6601-f223-414c-a39f-a98d002f8d00\" href=\"http://www.actiononhearingloss.org.uk/\">Action on Hearing Loss</a>  (www.actiononhearingloss.org.uk).</li><li><a data-hyperlink-id=\"58c299bb-0393-4551-afd7-a98d002f8d9b\" href=\"https://www.nhs.uk/conditions/\">NHS</a> — offers patient information on <a data-hyperlink-id=\"17362ba6-ef99-42ab-9d13-a98d002f8dcc\" href=\"https://www.nhs.uk/conditions/menieres-disease/\">Meniere's disease</a>.</li></ul></li></ul><!-- end field 247ca6ff-01be-4d7e-9f02-389c502e8794 --><!-- end item f67b3957-1d29-4f23-814b-7d01de617351 -->","subChapters":[{"id":"eeed1b00-9f30-5ae4-806b-e822bfc5d064","slug":"basis-for-recommendation-baa","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 084f0782-1533-4e0a-a7aa-1c6a06b21dc6 --><h4>Basis for recommendation</h4><!-- end field 084f0782-1533-4e0a-a7aa-1c6a06b21dc6 -->","summary":null,"htmlStringContent":"<!-- begin item baa4a9df-a88a-422a-844d-47005795cf1d --><!-- begin field 661492c7-cdaa-40ec-8bba-f3e9800e68cd --><h5>Reassurance</h5><ul><li>CKS advises offering reassurance to people with Meniere's disease based on prognostic information and expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Wipperman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Wright, 2015</a>]. </li></ul><h5>Advice to return if no improvement to exclude an alternative diagnosis</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice.</li><li>There are a number of differential diagnoses of Meniere's disease and it is important to exclude these before making a firm diagnosis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Dommaraju and Perera, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Nevoux et al, 2017</a>].<strong> </strong>This is emphasised in the 2015 Equilibrium Committee Amendment to the 1995 AAO-HNS Guidelines for the Definition of Meniere’s Disease which includes 'not better accounted for by another vestibular diagnosis' as a criterion for a definite diagnosis of Meniere's disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Gurkov et al, 2016</a>]. </li></ul><h5>Advice for people with sudden attacks of vertigo</h5><ul><li>The recommendation to keep medication readily accessible and consider the risks of certain activities is pragmatic, based on what CKS considers to be good clinical practice. </li></ul><h5>Driving advice</h5><ul><li>This recommendation is based on information in the Driver and Vehicle Licensing Agency (DVLA) publication <em>Assessing fitness to drive: a guide for medical professionals </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">DVLA, 2017</a>].</li></ul><h5>Offering information and support</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice.</li></ul><!-- end field 661492c7-cdaa-40ec-8bba-f3e9800e68cd --><!-- end item baa4a9df-a88a-422a-844d-47005795cf1d -->","subChapters":[]}]},{"id":"ceabe852-8adf-57dc-aa08-6ba6fd47b635","slug":"symptomatic-treatment-for-acute-attack","fullItemName":"Symptomatic treatment for acute attack","depth":3,"htmlHeader":"<!-- begin field c0652624-262b-406b-a07a-2d0cd0d62d2e --><h3>What symptomatic treatment is recommended for an acute attack of Meniere's disease?</h3><!-- end field c0652624-262b-406b-a07a-2d0cd0d62d2e -->","summary":null,"htmlStringContent":"<!-- begin item 9dc5558b-792b-4431-8db0-f1356af3b4cd --><!-- begin field a89eb9e0-4698-4df6-a61a-2f038e4cbbb8 --><ul><li><strong>If symptoms are severe,</strong> hospital admission may be required for intravenous (IV) labyrinthine sedatives and fluids to maintain hydration, and nutrition.</li><li><strong>To <em>rapidly </em>relieve (severe) nausea or vomiting</strong> associated with Meniere's disease, consider administration of buccal prochlorperazine, or a deep intramuscular injection of prochlorperazine or cyclizine.</li><li><strong>To help alleviate nausea, vomiting, and vertigo in other people with Meniere's disease,</strong> consider prescribing a short course (7 days, 14 days if required previously) of prochlorperazine, or an antihistamine (for example cinnarizine, cyclizine, or promethazine teoclate). <ul><li>If the person has had previous attacks of Meniere's disease and responded well to one of these drugs, consider trying that drug as first-line treatment. Always consider the person's preferences when choosing the drug and delivery route. For more information, see <a class=\"topic-reference internal-reference\" href=\"/topics/menieres-disease/prescribing-information/\">Prescribing information</a>.</li></ul></li><li><strong>If the person's symptoms deteriorate or do not improve after 5–7 days,</strong> reassess to exclude an alternative diagnosis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/vertigo/\">Vertigo</a>. </li><li>For more information on managing the symptom of tinnitus in a person with Meniere's disease, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/tinnitus/\">Tinnitus</a>.</li></ul><!-- end field a89eb9e0-4698-4df6-a61a-2f038e4cbbb8 --><!-- end item 9dc5558b-792b-4431-8db0-f1356af3b4cd -->","subChapters":[{"id":"93e30bf4-5998-5edb-91de-53b73df0efc6","slug":"basis-for-recommendation-a30","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0f6b0a60-a5a2-48aa-91c6-0ab2a6e8c4f0 --><h4>Basis for recommendation</h4><!-- end field 0f6b0a60-a5a2-48aa-91c6-0ab2a6e8c4f0 -->","summary":null,"htmlStringContent":"<!-- begin item a30dcb03-3667-4764-8536-923996600309 --><!-- begin field bb5f2636-b6e6-4a6a-9d99-ba04e4f5112a --><h5>Admission to hospital</h5><ul><li>This recommendation is pragmatic and is based on what CKS considers to be good clinical practice. </li></ul><h5>Symptomatic drug treatment</h5><ul><li>Evidence for the use of symptomatic drug treatment for Meniere's disease is lacking. The recommendation for the vestibular suppressant medications prochlorperazine and antihistamines (cinnarizine, cyclizine, and promethazine teoclate) to relieve vertigo symptoms is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Foster, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Espinosa-Sanchez and Lopez-Escamez, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BMJ Best Practice, 2017</a>] and the fact they are all licensed for use in people with Meniere's disease, and for nausea, vomiting, and vertigo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2015a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2017b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">MHRA, 2017</a>].</li><li>Some experts note that the sedative and anxiolytic effects of benzodiazepines may be useful [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Foster, 2015</a>], but CKS does not recommend their use because there is a lack of evidence, they are not licensed for this indication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BNF 74, 2017</a>], and there is the potential for dependence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BMJ Best Practice, 2017</a>].  </li><li>The recommendation to try a drug which has previously been effective and to consider the person's preferences is pragmatic and based on what CKS considers to be good clinical practice.</li></ul><h5>Short-term use of symptomatic drug treatment</h5><ul><li>CKS only recommends short-term use of symptomatic drug treatments because experts are of the opinion that regular, long-term use of vestibular suppressants can interfere with vestibular compensation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>].<strong> </strong>Other experts only recommend use during acute attacks, noting that they do not affect the progression of the disorder [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Foster, 2015</a>]. </li></ul><h5>Reassessment after 5–7 days</h5><ul><li>The recommendation to reassess after 5–7 days if the person's symptoms have not improved is pragmatic, based on the fact that there are a number of differential diagnoses of Meniere's disease and severe vertigo associated with an acute attack of Meniere's disease does not usually last longer than 24 hours [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>]. Over time, people with Meniere's disease can report symptoms of positional vertigo or imbalance between acute attacks due to vestibular function loss [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Wipperman, 2014</a>].<strong> </strong></li></ul><!-- end field bb5f2636-b6e6-4a6a-9d99-ba04e4f5112a --><!-- end item a30dcb03-3667-4764-8536-923996600309 -->","subChapters":[]}]},{"id":"fde13508-4aa5-5da4-b511-13d29ac0a6ff","slug":"preventing-recurrent-attacks","fullItemName":"Preventing recurrent attacks","depth":3,"htmlHeader":"<!-- begin field 4685d4e8-5d68-428e-9796-7fa286dc3c3a --><h3>How should I try and prevent recurrent attacks of Meniere's disease?</h3><!-- end field 4685d4e8-5d68-428e-9796-7fa286dc3c3a -->","summary":null,"htmlStringContent":"<!-- begin item 80a39884-29a0-4785-b995-e1b877f5a618 --><!-- begin field a3eea936-96d9-474b-900a-bb2cd62ee73a --><ul><li><strong>Consider prescribing a trial of betahistine</strong> to reduce the frequency and severity of attacks of hearing loss, tinnitus, and vertigo. </li><li><strong>If betahistine does not provide the clinical benefit required,</strong> and there are recurrent attacks of Meniere's disease despite its use, refer to an Ear, Nose, and Throat (ENT) specialist for consideration of other possible interventions.</li></ul><!-- end field a3eea936-96d9-474b-900a-bb2cd62ee73a --><!-- end item 80a39884-29a0-4785-b995-e1b877f5a618 -->","subChapters":[{"id":"b5fdde58-65d0-5489-8eed-0e4240792a9a","slug":"basis-for-recommendation-31e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field da589d07-f6f0-499b-910a-e6ce03d2f84f --><h4>Basis for recommendation</h4><!-- end field da589d07-f6f0-499b-910a-e6ce03d2f84f -->","summary":null,"htmlStringContent":"<!-- begin item 31e670e8-4f9b-4771-a2dd-9dc01df9c1c4 --><!-- begin field b6300f21-9ca6-47ab-bf90-ba02483f3d07 --><h5>Betahistine</h5><ul><li>The basis for this recommendation is that betahistine is licensed for treating hearing loss, tinnitus, and vertigo associated with Meniere's disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">ABPI Medicines Compendium, 2016a</a>], and it is often used in clinical practice for this purpose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Wipperman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Foster, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Nevoux et al, 2017</a>]. However, evidence regarding its use for Meniere's disease is inconclusive:<ul><li>A Cochrane systematic review (search date September 2015) on the use of betahistine for the symptom of vertigo found 16 studies comparing betahistine with placebo (n = 953). Five studies specifically included people with clinically defined Meniere's disease. On the basis of this low-quality evidence, the Cochrane authors concluded that betahistine may be beneficial in terms of reducing vertigo symptoms in people with vertigo from a variety of causes. However, there was a high level of heterogeneity between the studies, necessitating caution in interpretation of the results [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Murdin et al, 2016</a>]. </li><li>A subsequent long-term randomized controlled trial studied the efficacy and safety of betahistine treatment in patients with Meniere's disease. This found that, although betahistine was well tolerated, there was no clear evidence that nine months of betahistine treatment (at low or high dose) results in a clinical reduction in the number of attacks compared with placebo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Adrion et al, 2016</a>]. </li></ul></li></ul><h5>Referral if no clinical benefit with betahistine</h5><ul><li>CKS recommends referral if the person does not experience improvement with betahistine because a specialist may suggest other secondary care interventions. These include vestibular rehabilitation; diuretics; intratympanic gentamicin or corticosteroids; external pressure devices; endolymphatic shunts or sac surgery; labyrinthectomy or vestibular nerve section [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Pullens et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Ludman, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Harcourt et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Foster, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Tassinari et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Wright, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Crowson et al, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Espinosa-Sanchez and Lopez-Escamez, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">BMJ Best Practice, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menieres-disease/references/\">Nevoux et al, 2017</a>].</li></ul><!-- end field b6300f21-9ca6-47ab-bf90-ba02483f3d07 --><!-- end item 31e670e8-4f9b-4771-a2dd-9dc01df9c1c4 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}